Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies....more
3/31/2025
/ Biotechnology ,
Class Action ,
Clinical Trials ,
FDA Approval ,
Health Care Providers ,
Insider Trading ,
Life Sciences ,
Medical Devices ,
Medicare ,
Motion to Dismiss ,
Pharmaceutical Industry ,
Publicly-Traded Companies ,
Scienter ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act of 1934 ,
Securities Fraud ,
Securities Litigation
The U.S. Department of Justice (“DOJ”) recently announced that over $5.6 billion in False Claims Act (“FCA”) settlements and judgments had been reached during the 2021 fiscal year, with over $5 billion of those settlements...more
3/8/2022
/ Anti-Kickback Statute ,
Clinical Laboratories ,
Department of Justice (DOJ) ,
Digital Health ,
Enforcement Actions ,
False Claims Act (FCA) ,
Health Care Providers ,
Health Technology ,
Healthcare Fraud ,
Life Sciences ,
Medical Devices ,
Pharmaceutical Industry ,
Private Equity ,
Telehealth
Securities Class Action Against Swiss-Based Company Dismissed On Forum Non Conveniens Grounds; Second Circuit Finds Strong Inference of “Conscious Recklessness” In Allegations And Reverses Dismissal of Securities Suit Against...more
8/25/2020
/ Bribery ,
Class Action ,
Cross-Border Transactions ,
Department of Justice (DOJ) ,
Dismissals ,
False Statements ,
Foreign Corporations ,
Foreign Corrupt Practices Act (FCPA) ,
Forum Non Conveniens ,
Forum Selection ,
Government Investigations ,
Investors ,
Misleading Statements ,
Omissions ,
Pharmaceutical Industry ,
Popular ,
Putative Class Actions ,
Real Estate Investments ,
Recklessness ,
Reversal ,
Rule 10b-5 ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act ,
Securities Litigation ,
Settlement